Prion diseases are caused by a conformational conversion of the cellular prion protein (PrPC) to a pathological conformer (PrPSc). The “prion-only” hypothesis suggests that PrPSc is the infectious agent that propagates the disease acting as a template for the conversion of PrPC. In 2001, we developed a novel technique, called protein misfolding cyclic amplification (PMCA), which mimics in vitro this pathological process in an accelerated way. Thereby, a minimal amount of PrPSc can be amplified several million folds, providing an important tool for the diagnosis and investigation of prion biology, and the molecular mechanism of prion conversion. PMCA also offers a great platform for the study and amplification of the protein misfolding process associated with other neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Here we are updating this previously published chapter to incorporate recent advances.
Protein Misfolding Cyclic Amplification / F. Moda, S. Pritzkow, C. Soto - In: Prions and Diseases / [a cura di] W.-Q. Zou, P. Gambetti. - Riedizione. - [s.l] : Springer International Publishing, 2023. - ISBN 9783031205644. - pp. 637-652 [10.1007/978-3-031-20565-1_31]
Protein Misfolding Cyclic Amplification
F. ModaPrimo
;
2023
Abstract
Prion diseases are caused by a conformational conversion of the cellular prion protein (PrPC) to a pathological conformer (PrPSc). The “prion-only” hypothesis suggests that PrPSc is the infectious agent that propagates the disease acting as a template for the conversion of PrPC. In 2001, we developed a novel technique, called protein misfolding cyclic amplification (PMCA), which mimics in vitro this pathological process in an accelerated way. Thereby, a minimal amount of PrPSc can be amplified several million folds, providing an important tool for the diagnosis and investigation of prion biology, and the molecular mechanism of prion conversion. PMCA also offers a great platform for the study and amplification of the protein misfolding process associated with other neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases. Here we are updating this previously published chapter to incorporate recent advances.File | Dimensione | Formato | |
---|---|---|---|
978-3-031-20565-1_31.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
680.51 kB
Formato
Adobe PDF
|
680.51 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.